### The prevalence of chronic kidney disease 1

# in people with severe mental illness: A 2

#### systematic review protocol 3

- 4 Carswell, C.<sup>1</sup>, Bramham, K.<sup>2</sup>, Chilcot, J.<sup>3</sup>, Jacobs, R.,<sup>4</sup> Osborn, D.<sup>5</sup>, and Siddigi, N.<sup>1,6,7</sup>
- 5
- 6 <sup>1</sup> Department of Health Sciences, University of York, York, UK
- 7 <sup>2</sup> King's College Hospital NHS Trust, London, UK
- 8 <sup>3</sup> Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- 9 <sup>4</sup>Centre for Health Economics, University of York, York, UK
- 10 <sup>5</sup>Division of Psychiatry, University College London, London, United Kingdom
- 11 <sup>6</sup>Hull York Medical School, York, UK
- 12 <sup>7</sup> Bradford District Care NHS Foundation Trust, Bradford, UK

13

#### Abstract 14

#### 15 Background

16 People with severe mental illness (SMI) are more likely to develop long-term physical health

17 conditions, including type 2 diabetes and cardiovascular disease, compared to people without SMI.

18 This contributes to an inequality in life expectancy known as the 'mortality gap'. Chronic kidney

- 19 disease (CKD) is a growing global health concern set to be the 5th leading cause of life-years lost by
- 20 2040. However, there is limited research exploring the relationship between CKD and SMI. This
- 21 systematic review will aim to examine the prevalence and incidence of CKD among people with SMI.
- 22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 23 Methods

- 24 We will search Medline, Embase, PsycINFO, CINAHL, Scopus and Web of Science for primary
- 25 epidemiological research reporting the prevalence or incidence of CKD among people with SMI in
- 26 any setting. Retrieved records will be managed in Covidence and screened by two independent
- 27 reviewers. Data will be extracted from included studies using a piloted data extraction form, and the
- 28 quality of studies will be evaluated using the appropriate JBI Critical Appraisal Checklist. The
- 29 certainty of evidence will be assessed using the Grading of Recommendations, Assessment,
- 30 Development, and Evaluations (GRADE) approach. Data from the included studies will be narratively
- 31 synthesised. Meta-analyses will be conducted using random effects models to examine the
- 32 prevalence and incidence of CKD among people with SMI.
- 33

#### 34 Discussion

35

There is limited research exploring the relationship between CKD and SMI, and this proposed
systematic review will be the first to examine the prevalence of CKD among people with SMI. This
review will highlight the extent of the problem and provide a foundation for future research to
improve health outcomes for people with SMI.

# 46 Introduction

47	People with severe mental illness (SMI; enduring conditions that can present with psychosis,
48	including schizophrenia and bipolar disorder) die, on average, 15-20 years earlier than people who
49	do not have SMI [1, 2]. This inequality, known as the mortality gap, is widening over time and is
50	largely driven by higher rates of long-term physical health conditions and associated poor outcomes
51	[1, 3]. The leading cause of death among people with SMI is cardiovascular disease, accounting for
52	70% of all deaths in people with either bipolar disorder or schizophrenia [4]. The risk of sudden
53	cardiac death or cardiovascular mortality is five times higher in people with SMI, compared to
54	people without SMI [4].
55	
56	While research has explored the relationship between SMI and long-term conditions such as
57	cardiovascular disease [5] and type 2 diabetes [6], chronic kidney disease (CKD) has not received the
58	same attention [7]. CKD is a condition characterised by progressive loss of kidney function that can
59	eventually lead to kidney failure (CKD stage 5), requiring kidney replacement therapies such as a
60	transplant or dialysis [8]. The current global estimate for the prevalence of CKD is 843.6 million [9].
61	However, prevalence is increasing, and CKD is set to become the 5th leading cause of life-years lost
62	globally by 2040 [10].
63	

There is evidence to suggest that people living with SMI could be at higher risk of developing CKD [7]. Antipsychotic medication and mood stabilisers, commonly used in the treatment of SMI, can induce metabolic syndrome, and increase the risk of diabetes mellitus and hypertension which are the leading causes of CKD worldwide [11]. Lithium, a common mood stabiliser used in the treatment of bipolar disorder, is nephrotoxic [12], can induce acute kidney injury at high doses, and increases the risk of CKD with long-term use [13]. Antipsychotic medications may also increase the risk of developing CKD [14]. Although not known to be directly nephrotoxic, this risk likely results from the

71	significant cardiometabolic disturbances that can result as a side-effect of antipsychotic medication
72	[15], and the well-established relationship between CKD and poor cardiometabolic health [16]. In
73	addition, lifestyle and behavioural factors such as smoking [17], diets high in fat, salt and sugar [18],
74	and high levels of sedentary behaviour are known risk factors for CKD, while also being more
75	common among people with SMI [19-22].
76	
77	Identifying people at risk of CKD is crucial to facilitate early identification and intervention [23]. Early
78	intervention can prevent or slow progression to the later stages of CKD, and reduce the risk of
79	cardiovascular mortality [24]. This is pertinent as cardiovascular complications are the leading cause
80	of death related to both CKD and SMI [25, 26], yet research suggests early intervention is not
81	occurring in this population. For example, people with SMI have lower rates of accessing nephrology
82	care [27], are less likely to receive dialysis [28, 29], and are less likely to be assessed for
83	transplantation when compared to people without SMI [30].
84	
85	To advocate for improved identification and appropriate care for people with co-existing SMI and
86	CKD, there is a need to understand the epidemiology of this co-morbidity, including prevalence and
87	incidence. Therefore, a systematic review is needed to understand the extent of the problem and
88	provide a foundation for future research.

# 89 Objectives

- 90 This review has two overarching objectives:
- Examine the prevalence and incidence of CKD among people with SMI.
- 92 Compare the prevalence and incidence of CKD among people with SMI, to those who do not
   93 have SMI.

# 94 Material and Methods

95 This protocol has been prospectively registered on the PROSPERO database (ID: CRD42024527215)

96 [31] and is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-

97 Analysis Protocols (PRISMA-P) statement [32].

# 98 Search strategy and information sources

99 We will search electronic databases, including Medline, Embase, PsycInfo, CINAHL, Scopus and Web 100 of Science from conception to June 2024. No restrictions on year of publication or publication status 101 will be applied during the initial searches, to enable exploration of prevalence and incidence across 102 time. All searches will be re-run before the final analysis to ensure all relevant publications are 103 included. Search strings for electronic databases were developed according to the exposure (severe 104 mental illness), outcome (chronic kidney disease) and study design (epidemiological designs). Search 105 terms were identified from relevant systematic reviews capturing similar concepts and were refined 106 through initial piloting and consultation with subject librarians. The full MEDLINE strategy can be 107 found in Appendix 1.

108

109 We will review reference lists of included articles, and seminal publications and search key journals 110 in the subject area to ensure all relevant publications have been identified. This will include the 111 Clinical Journal of the American Society of Nephrology, the International Journal of Nephrology, 112 JAMA Psychiatry, The Lancet Psychiatry, BMC Nephrology and BMC Psychiatry. We will also search 113 grey literature repositories including ProQuest Dissertations and Open Science Framework (OSF). 114 Experts in the field of severe mental illness and kidney disease, and authors of relevant studies, will 115 be consulted to identify any potential key publications that could have been missed in the initial 116 searches.

# 117 Eligibility criteria

- 118 Study design
- 119 Inclusion criteria
- Epidemiological observational studies, including cohort, case-control and cross-sectional
- 121 studies will be included.
- 122

#### 123 Exclusion criteria

- Qualitative studies, randomised controlled trials, and quasi-experimental studies will be
- 125 excluded. While experimental studies may report the proportions of participants with
- 126 certain conditions, they are not designed to determine the prevalence or incidence of a
- 127 condition and often include super-selected samples which may not be representative of the
- 128 population. Therefore, they will be excluded.
- Case reports, editorials, commentaries, and protocols will be excluded.

### 130 Population/ Exposure

#### 131 Inclusion criteria

• Adults aged 18 years and over

• The population includes participants who have a diagnosis of SMI. SMI will be defined in this

134 review as psychiatric conditions that can present with psychosis (not induced by substances

- 135 or caused by an organic condition) [33-36]. These conditions include schizophrenia,
- 136 schizoaffective disorder, bipolar disorder, severe depression with psychosis, other specified
- 137 psychosis, and persistent delusional disorders. Any report of participants having a diagnosis
- 138 of these conditions, using any standardised diagnostic tool (including the International
- 139 Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM)) will be
- included.

141

### 142 Exclusion criteria

- Participants under the age of 18. If the study has also collected data from adults (over and
   those under 18, it will be included if the data is presented separately and can be analysed
   separately.
- Studies which focus exclusively on conditions which do not meet the classification for SMI,
   for example, anxiety disorders, depressive disorders which do not present with psychosis,
   eating disorders, and personality disorders, will be excluded. Studies focused on depressive
   disorders, in general, will only be included if they report results for severe depression with
   psychosis separately. Studies which focus on a variety of mental health conditions will be
   included if they report findings in a way that allows identification and separate analysis of
   participants with SMI.
- Studies, where different mental health diagnoses or categories are not reported separately
   (for example, where results for participants with SMI are aggregated with participants who
   have common mental disorders, such as depression or anxiety), will only be included if more
- 156 than 50% of the sample are known to have SMI.
- Studies where the proportion of participants with SMI cannot be determined will be
  excluded.

159 Outcome

#### 160 Inclusion criteria

- Studies which report the prevalence or incidence of CKD, at any stage, among people with
   SMI.
- Studies which compare the prevalence or incidence of CKD, at any stage, among the general
   population (or those without SMI) to people with SMI.

#### 166 Exclusion criteria

167	٠	Studies which focus on the prevalence or incidence of acute kidney injury (AKI), without
168		reporting the prevalence or incidence of CKD, among people with SMI.
169	•	Studies which report the prevalence of SMI among people with CKD (where a population
170		with CKD is used as the denominator population or exposure, and SMI is reported as the
171		outcome).

# 172 Study selection

173 Records will be imported into Covidence for screening [37]. Two independent reviewers will
174 complete the title and abstract screening, and disagreements will be resolved through discussion. If
175 an agreement cannot be reached, the decision will be made by a third reviewer. Following title and
176 abstract screening the full texts of eligible studies will be imported into Covidence to undergo full177 text screening, which again will be completed by two independent reviewers, with disagreements
178 resolved through discussion or a decision from a third reviewer.

### 179 Data extraction

180 Two independent reviewers will perform the data extraction. A data extraction form will be 181 developed in Excel and initially piloted by the two reviewers on a subset of included studies to 182 ensure the form is fit for purpose. Disagreements and inconsistencies in data extraction will be 183 reviewed and discussed, and the initial data extraction form will be refined as needed. Following the 184 piloting, data extraction will be performed again by two reviewers, with any disagreements being 185 resolved by a third reviewer who has not previously been involved with the data extraction process. 186 Articles reporting data from the same study in different publications will be grouped at this stage 187 and presented within a single study. The data extraction form will capture the author's names, date 188 of publication(s), publication type(s), country, study design, total sample size, number of participants

with SMI, diagnoses, mean age, percentage of females, ethnicity, medication use, data collection
 procedures, statistical approach, summary results (prevalence, incidence and comparisons), and
 covariates considered.

# 192 Risk of bias assessment

Two independent reviewers will use the appropriate JBI (formerly Joanna Briggs Institute) Critical Appraisal Checklist to evaluate the risk of bias in each of the included studies. The JBI Critical Appraisal Checklists assess the trustworthiness and quality of published research and include checklists for a range of different methodologies including cohort studies, case-control studies and cross-sectional studies [38]. Any disagreement in the assessment of the two independent reviewers will be settled through discussion, or if an agreement cannot be reached, through a decision made by a third reviewer who has not previously been involved with the critical appraisal process.

### 200 Certainty of evidence

201 We will use the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) 202 approach to determine the certainty of the evidence [39]. GRADE outlines five domains that are 203 assessed to determine certainty: risk of bias, inconsistency, indirectness, imprecision and publication 204 bias. GRADE is predominantly used to assess certainty in intervention research and has not been 205 formally adapted for the use in systematic reviews of prevalence or incidence. However, previous 206 systematic reviews have used GRADE to evaluate the certainty of prevalence studies with adapted 207 components [40]. We will use the GRADE guidance for baseline risk or overall prognosis, as 208 recommended by Borges Migliavaca et al. (2020) for systematic reviews of prevalence [41].

### 209 Data synthesis

210 The data from the included studies will be presented in tables and narratively synthesised to provide 211 a summary of the study characteristics and findings. Meta-analyses will also be conducted using 212 random effects models assuming an adequate number of studies (at least two) and clinical similarity 213 to justify the pooling of prevalence or incidence rate. The heterogeneity across studies will be 214 assessed through visual inspection of forest plots, a chi-squared test for heterogeneity, and the I<sup>2</sup> 215 statistic. However, as meta-analyses of prevalence tend to have high  $I^2$  statistics [42], we will not 216 apply statistical thresholds to determine whether it is appropriate to pool the data. We will 217 transform the raw proportions using the Freeman-Tukey variant of the arcsine square root 218 transformation [43]. For objective 1, the pooled prevalence or incidence rate of CKD among people 219 with SMI will be presented with 95% CIs. For objective 2, we will undertake a meta-analysis of 220 prevalence or incidence rate comparisons if the data is available. These will be presented as pooled 221 risk ratios or odds ratios, with 95% Cls. If there is sufficient data, we will conduct subgroup analyses 222 to explore the differences in CKD across different types of SMI diagnosis, CKD stage, medication, 223 gender, age, geography (Low- and middle- income countries or high-income countries), setting 224 (communtiy or inpatient), and year of data collection.

# 225 Discussion

This proposed review aims to address a crucial gap in the evidence base by synthesising the literature on the prevalence of CKD among people with SMI. Previous systematic reviews have established that people with SMI are at significantly higher risk of developing long-term physical health conditions, including type 2 diabetes [5, 6]. However, the available literature on the prevalence or incidence of CKD has not yet been synthesised in a systematic review.

# 231 Implications for research, practice or policy

232	By examining the prevalence of CKD in people with SMI, this review will highlight the need for future
233	research and policy change. Most research to date in this population has focused on the role of
234	lithium as a risk factor for CKD [44], and there is limited research exploring other, potentially
235	modifiable, risk factors [7]. Establishing the prevalence of CKD among people with SMI (including
236	those not on lithium treatment) is an important step towards identifying key modifiable risk factors
237	that contribute to the development and progression of CKD in this population. This will enable not
238	just more targeted approaches to screening and monitoring to facilitate early intervention but could
239	also inform the development of future interventions to improve CKD outcomes for people with SMI.
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	
251	

# 252 References

253

254 1. Fiorillo A, Sartorius N. Mortality gap and physical comorbidity of people with severe

255 mental disorders: the public health scandal. Annals of General Psychiatry. 2021;20(1):52.

256 doi: 10.1186/s12991-021-00374-y.

257 2. Siddiqi N, Doran T, Prady SL, Taylor J. Closing the mortality gap for severe mental

258 illness: Are we going in the right direction? British Journal of Psychiatry. 2017;211(3):130-1.

259 Epub 2018/01/02. doi: 10.1192/bjp.bp.117.203026.

260 3. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with

261 bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry.

262 2017;211(3):175-81. Epub 20170706. doi: 10.1192/bjp.bp.117.202606. PubMed PMID:

- 263 28684403; PubMed Central PMCID: PMCPMC5579328.
- Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe
   mental illness. Nature Reviews Cardiology. 2021;18(2):136-45. doi: 10.1038/s41569-020 00463-7.

267 5. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al.

268 Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and

specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and

270 113,383,368 controls. World Psychiatry. 2017;16(2):163-80. doi:

271 <u>https://doi.org/10.1002/wps.20420</u>.

272 6. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes

273 mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a

systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166-74. doi:

275 <u>https://doi.org/10.1002/wps.20309</u>.

276 7. Carswell C, Cogley C, Bramham K, Chilcot J, Noble H, Siddiqi N. Chronic kidney

disease and severe mental illness: a scoping review. Journal of Nephrology.

278 2023;36(6):1519-47. doi: 10.1007/s40620-023-01599-8.

279 8. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney

280 disease. The Lancet. 2021;398(10302):786-802. doi: https://doi.org/10.1016/S0140-

281 <u>6736(21)00519-5</u>.

282 9. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int

283 Suppl (2011). 2022;12(1):7-11. Epub 20220318. doi: 10.1016/j.kisu.2021.11.003. PubMed

284 PMID: 35529086; PubMed Central PMCID: PMCPMC9073222.

285 10. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al.

286 Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for

287 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and

288 territories. Lancet. 2018;392(10159):2052-90. Epub 20181016. doi: 10.1016/s0140-

289 6736(18)31694-5. PubMed PMID: 30340847; PubMed Central PMCID: PMCPMC6227505.

290 11. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic

kidney disease and the global public health agenda: an international consensus. Nature

292 Reviews Nephrology. 2024;20(7):473-85. doi: 10.1038/s41581-024-00820-6.

293 12. Grünfeld J-P, Rossier BC. Lithium nephrotoxicity revisited. Nature Reviews
294 Nephrology. 2009;5(5):270-6. doi: 10.1038/nrneph.2009.43.

295 13. Gupta S, Khastgir U. Drug information update. Lithium and chronic kidney disease:

296 debates and dilemmas. BJPsych Bull. 2017;41(4):216-20. doi: 10.1192/pb.bp.116.054031.

297 PubMed PMID: 28811917; PubMed Central PMCID: PMCPMC5537577.

298 14. Højlund M, Lund LC, Herping JLE, Haastrup MB, Damkier P, Henriksen DP. Second-

299 generation antipsychotics and the risk of chronic kidney disease: a population-based case-

300 control study. BMJ Open. 2020;10(8):e038247. doi: 10.1136/bmjopen-2020-038247.

301 15. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of

302 psychotropic medications. Horm Mol Biol Clin Investig. 2018;36(1). Epub 20180110. doi:

303 10.1515/hmbci-2017-0065. PubMed PMID: 29320364; PubMed Central PMCID:

304 PMCPMC6818518.

305 16. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. 306 Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart 307 Association, Circulation, 2023;148(20):1606-35, doi: 10.1161/CIR.00000000001184. 308 17. Fu YC, Xu ZL, Zhao MY, Xu K. The Association Between Smoking and Renal 309 Function in People Over 20 Years Old. Front Med (Lausanne). 2022;9:870278. Epub 310 20220603. doi: 10.3389/fmed.2022.870278. PubMed PMID: 35721101: PubMed Central 311 PMCID: PMCPMC9205397.

31218.Kuma A, Kato A. Lifestyle-Related Risk Factors for the Incidence and Progression of

313 Chronic Kidney Disease in the Healthy Young and Middle-Aged Population. Nutrients.

314 2022;14(18). Epub 20220914. doi: 10.3390/nu14183787. PubMed PMID: 36145162;

315 PubMed Central PMCID: PMCPMC9506421.

316 19. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, et al.

Cigarette Smoking by Patients With Serious Mental Illness, 1999–2016: An Increasing

318 Disparity. Psychiatric Services. 2017;69(2):147-53. doi: 10.1176/appi.ps.201700118.

319 20. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al.

320 Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder

and major depressive disorder: a global systematic review and meta-analysis. World

322 Psychiatry. 2017;16(3):308-15. doi: <u>https://doi.org/10.1002/wps.20458</u>.

323 21. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The

324 dietary pattern of patients with schizophrenia: A systematic review. Journal of Psychiatric

325 Research. 2013;47(2):197-207. doi: <u>https://doi.org/10.1016/j.jpsychires.2012.10.005</u>.

326 22. Teasdale SB, Ward PB, Samaras K, Firth J, Stubbs B, Tripodi E, et al. Dietary intake

327 of people with severe mental illness: systematic review and meta-analysis. The British

328 Journal of Psychiatry. 2019;214(5):251-9. Epub 2019/02/20. doi: 10.1192/bjp.2019.20.

329 23. Okpechi IG, Caskey FJ, Gaipov A, Tannor EK, Noubiap JJ, Effa E, et al. Early

330 Identification of CKD-A Scoping Review of the Global Populations. Kidney Int Rep.

331 2022;7(6):1341-53. Epub 20220406. doi: 10.1016/j.ekir.2022.03.031. PubMed PMID:

332 35685314; PubMed Central PMCID: PMCPMC9171699.

- 333 24. Neuen BL, Jun M, Wick J, Kotwal S, Badve SV, Jardine MJ, et al. Estimating the
- 334 population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic
- 335 kidney disease: a cross-sectional observational study using routinely collected Australian
- 336 primary care data. The Lancet Regional Health Western Pacific. 2024;43. doi:
- 337 10.1016/j.lanwpc.2023.100988.
- 338 25. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic
- 339 Kidney Disease. Circulation. 2021;143(11):1157-72. doi:
- 340 10.1161/CIRCULATIONAHA.120.050686.
- 341 26. de Mooij LD, Kikkert M, Theunissen J, Beekman ATF, de Haan L, Duurkoop P, et al.
- 342 Dying Too Soon: Excess Mortality in Severe Mental Illness. Front Psychiatry. 2019;10:855.
- 343 Epub 20191206. doi: 10.3389/fpsyt.2019.00855. PubMed PMID: 31920734; PubMed Central
- 344 PMCID: PMCPMC6918821.
- 345 27. Hsu Y-H, Cheng J-S, Ouyang W-C, Lin C-L, Huang C-T, Hsu C-C. Lower Incidence
- 346 of End-Stage Renal Disease but Suboptimal Pre-Dialysis Renal Care in Schizophrenia: A
- 347 14-Year Nationwide Cohort Study. PLOS ONE. 2015;10(10):e0140510. doi:
- 348 10.1371/journal.pone.0140510.
- 349 28. Boyle SM, Fehr K, Deering C, Raza A, Harhay MN, Malat G, et al. Barriers to kidney
- 350 transplant evaluation in HIV-positive patients with advanced kidney disease: A single-center
- 351 study. Transplant Infectious Disease. 2020;22(2):e13253. doi:
- 352 <u>https://doi.org/10.1111/tid.13253</u>.
- 353 29. Tzur Bitan D, Krieger I, Berkovitch A, Comaneshter D, Cohen A. Chronic kidney
- disease in adults with schizophrenia: A nationwide population-based study. General Hospital
- 355 Psychiatry. 2019;58:1-6. doi: <u>https://doi.org/10.1016/j.genhosppsych.2019.01.007</u>.
- 356 30. Bayat S, Frimat L, Thilly N, Loos C, Briançon S, Kessler M. Medical and non-medical
- 357 determinants of access to renal transplant waiting list in a French community-based network
- of care. Nephrology Dialysis Transplantation. 2006;21(10):2900-7. doi: 10.1093/ndt/gfl329.

31. 359 Carswell CC, Joseph; Jacobs, Rowena; Siddigi, Najma; Osborn, David. The 360 prevalence of chronic kidney disease amongst people with severe mental illness: a 361 systematic review and meta-analysis.: PROSPERO: 2024. 362 32. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred 363 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 364 statement, Systematic Reviews, 2015;4(1);1, doi: 10.1186/2046-4053-4-1. 365 33. Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft DM, et al. Inequalities in 366 physical comorbidity: a longitudinal comparative cohort study of people with severe mental 367 illness in the UK. BMJ Open, 2015;5(12):e009010. doi: 10.1136/bmiopen-2015-009010. 368 34. Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of 369 diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe 370 mental illnesses: Systematic review and metaanalysis. BMC Psychiatry. 2008;8(1):84. doi: 371 10.1186/1471-244X-8-84. 372 35. Das-Munshi J, Chang C-K, Dutta R, Morgan C, Nazroo J, Stewart R, et al. Ethnicity

and excess mortality in severe mental illness: a cohort study. The Lancet Psychiatry.

374 2017;4(5):389-99. doi: 10.1016/S2215-0366(17)30097-4.

375 36. Taylor J, Stubbs B, Hewitt C, Ajjan RA, Alderson SL, Gilbody S, et al. The

376 Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving

377 Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-

378 Analysis. PLOS ONE. 2017;12(1):e0168549. doi: 10.1371/journal.pone.0168549.

379 37. Innovation. VH. Covidence systematic review software.

380 38. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for

381 systematic reviews of observational epidemiological studies reporting prevalence and

382 cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-53. doi:

383 10.1097/xeb.000000000000054. PubMed PMID: 26317388.

384 39. Schünemann HB, Jan; Guyatt, Gordon; Oxman, Andrew. GRADE Handbook 2013.

385 Available from: <u>https://gdt.gradepro.org/app/handbook/handbook.html</u>.

386	40.	Edwards J, Hayden J, Asbridge M, Gregoire B, Magee K. Prevalence of low back
387	pain in	emergency settings: a systematic review and meta-analysis. BMC Musculoskeletal
388	Disord	ers. 2017;18(1):143. doi: 10.1186/s12891-017-1511-7.

- 389 41. Borges Migliavaca C, Stein C, Colpani V, Barker TH, Munn Z, Falavigna M. How are
- 390 systematic reviews of prevalence conducted? A methodological study. BMC Med Res
- 391 Methodol. 2020;20(1):96. Epub 20200426. doi: 10.1186/s12874-020-00975-3. PubMed
- 392 PMID: 32336279; PubMed Central PMCID: PMCPMC7184711.
- 393 42. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al. Meta-

analysis of prevalence: statistic and how to deal with heterogeneity. Research Synthesis

395 Methods. 2022;13(3):363-7. doi: <u>https://doi.org/10.1002/jrsm.1547</u>.

- 396 43. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for
- 397 systematic reviews of observational epidemiological studies reporting prevalence and

398 cumulative incidence data. JBI Evidence Implementation. 2015;13(3).

- 399 44. Schoretsanitis G, de Filippis R, Brady BM, Homan P, Suppes T, Kane JM.
- 400 Prevalence of impaired kidney function in patients with long-term lithium treatment: A
- 401 systematic review and meta-analysis. Bipolar Disorders. 2022;24(3):264-74. doi:
- 402 <u>https://doi.org/10.1111/bdi.13154</u>.

403

404

405

406

407

# 409 Appendix 1

- 410 1. Exp Renal Dialysis/
- 411 2. h?emodialysis.tw,kf.
- 412 3. h?emofiltration.tw,kf.
- 413 4. h?emodiafiltration.tw,kf.
- 414 5. dialysis.tw,kf.
- 415 6. (Peritoneal adj1 (dialysis)).tw,kf.
- 416 7. (PD or CAPD or CCPD or APD).tw,kf.
- 417 8. Exp Renal Insufficiency/
- 418 9. Exp Kidney Failure/
- 419 10. Exp Renal Insufficiency, Chronic/
- 420 11. Exp Kidney Diseases/
- 421 12. Uremia/
- 422 13. (endstage adj1 (renal or kidney)).tw,kf
- 423 14. (ESRF or ESKF or ESRD or ESKD).tw,kf
- 424 15. (chronic adj1 (kidney or renal)).tw,kf
- 425 16. (CKF or CKD or CRF or CRD).tw,kf.
- 426 17. (predialysis).tw,kf.
- 427 18. (renal adj1 (transplant\* or graft)).tw,kf.
- 428 19. (kidney adj1 (transplant\* or graft)).tw,kf.
- 429 20. (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
- 430 OR 17 OR 18 OR 19)
- 431 21. Exp Schizophrenia/
- 432 22. Exp Affective disorders, psychotic/
- 433 23. Exp Bipolar disorder/

- 434 24. (bipolar adj1 (disorder\* or disease\* or illness\*)).tw,kf.
- 435 25. paranoid disorders/
- 436 26. Exp psychotic disorders/
- 437 27. schizo\*.tw,kf.
- 438 28. (mani\* adj3 depress\*).tw,kf.
- 439 29. (psychotic\* adj3 depress\*).tw,kf.
- 440 30. (severe\* adj3 affective\*).tw,kf.
- 441 31. (severe\* adj3 mental\*).tw,kf.
- 442 32. (severe\* adj3 depress\*).tw,kf.
- 443 33. (psychos#s adj3 depress\*).tw,kf.
- 444 34. (serious\* adj3 affective\*).tw,kf.
- 445 35. "serious mood\*".tw,kf.
- 446 36. (serious\* adj3 mental\*).tw,kf.
- 447 37. (serious\* adj3 depress\*).tw,kf.
- 448 38. "Severe mental\*".tw,kf.
- 449 39. Severe adj1 (mental\* or depress\*).tw,kf.
- 450 40. "Schizoaffective disorder".tw,kf
- 451 41. Exp Antipsychotic Agents/
- 452 42. Exp Antimanic Agents/
- 453 43. Exp Psychotropic Drugs/
- 454 44. (21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR
- 455 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43)
- 456 45. Exp epidemiologic studies/
- 457 46. Exp epidemiology/
- 458 47. epidemiolog\*.tw,kf.
- 459 48. Exp prevalence/

- 460 49. prevalence.tw,kf.
- 461 50. Exp incidence/
- 462 51. incidence.tw,kf.
- 463 52. Exp Observational Study/
- 464 53. observational.tw,kf.
- 465 54. Longitudinal Studies/
- 466 55. longitudinal.tw,kf.
- 467 56. Case-Control Studies/
- 468 57. Exp Cross-Sectional Studies/
- 469 58. Exp Cohort Studies/
- 470 59. "cohort".tw,kf.
- 471 60. Exp Risk/
- 472 61. Exp Risk Factors/
- 473 62. (45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR
- 474 59 OR 60 OR 61)
- 475 63. (20 AND 44 AND 62)